SCHEMBL1421811

SCHEMBL1421811

COc1cc(-c2oc3ccc(Br)cc3c(=O)c2O)ccc1OCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.61
TP53 P04637 8/20 0.61
KDM4E B2RXH2 7/20 0.61
CYP3A4 P08684 6/20 0.61
CASP1 P29466 4/20 0.61
CASP7 P55210 4/20 0.61
MEN1 O00255 4/20 0.61
KMT2A Q03164 4/20 0.61
ALDH1A1 P00352 4/20 0.61
LMNA P02545 3/20 0.61
HPGD P15428 3/20 0.61
HSD17B10 Q99714 3/20 0.61
RXFP1 Q9HBX9 3/20 0.55
ABCB1 P08183 2/20 0.54
ABCG2 Q9UNQ0 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.48
MAPK1 P28482 2/20 0.48
POLB P06746 1/20 0.48
ALOX15 P16050 1/20 0.48
CSNK2A2 P19784 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1421812 0.96 MAPT (0.61) MAPTTP53KDM4ECYP3A4CASP1
SCHEMBL1976582 0.89 ABCG2 (0.61) MAPTTP53KDM4ECYP3A4CASP1
SCHEMBL1973404 0.89 MAPT (0.58) MAPTTP53KDM4ECYP3A4CASP1
SCHEMBL1977887 0.89 MAPT (0.58) MAPTTP53KDM4ECYP3A4CASP1
SCHEMBL1422017 0.87 MAPT (0.76) MAPTTP53KDM4ECYP3A4CASP1
SCHEMBL1977218 0.86 ABCG2 (0.53) MAPTTP53KDM4ECYP3A4CASP1
SCHEMBL1976122 0.86 KDM4E (0.50) MAPTTP53KDM4ECYP3A4CASP1
SCHEMBL14696999 0.86 MAPT (0.60) MAPTTP53KDM4ECYP3A4CASP1
SCHEMBL1975287 0.84 ABCG2 (0.48) MAPTTP53KDM4ECYP3A4CASP1
SCHEMBL2397393 0.82 MAPT (0.75) MAPTTP53KDM4ECYP3A4CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AXOGLIA THERAPEUTICS (LU) 2011-06-16 US disclosed
EP-2297127-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AxoGlia Therapeutics S.A. (LU) 2011-03-23 EP disclosed
WO-2009130253-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AXOGLIA THERAPEUTICS S.A. (LU) 2009-10-29 WO disclosed
EP-2112145-A1 Chromenone derivatives useful for the treatment of neurodegenerative diseases AxoGlia Therapeutics S.A. (LU) 2009-10-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES PARK7, CDR2, SNCA MAPT 243/4885TP53 3362/4885KDM4E 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.